{
  "id": "5a86f074faa1ab7d2e00003a",
  "type": "factoid",
  "question": "With which cancers has the loss of SMARCB1 been associated?",
  "ideal_answer": "Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1 Loss of SMARCB1/INI1 expression is considered to be a hallmark for childhood chordomas (CCs)",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28825187",
    "http://www.ncbi.nlm.nih.gov/pubmed/28427232",
    "http://www.ncbi.nlm.nih.gov/pubmed/27635948",
    "http://www.ncbi.nlm.nih.gov/pubmed/24983247",
    "http://www.ncbi.nlm.nih.gov/pubmed/28812319"
  ],
  "snippets": [
    {
      "text": "We therefore sought to identify novel mutations to better understand chordoma biology and to potentially identify therapeutic targets",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983247",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "When this data is paired with the studies showing 18 of 21 chordoma samples displaying copy loss at the locus for CDKN2A, 17 of 21 chordoma samples displaying copy loss at PTEN, and 3 of 4 chordoma samples displaying deletion at the SMARCB1 locus, we can infer that a loss of heterozygosity at these three loci may play a significant role in chordoma pathogenesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SMARCB1/INI1 Involvement in Pediatric Chordoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27635948",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "All 8 cases were positive for brachyury, whereas there was no nuclear SMARCB1/INI1 expression in 4 of the 8 cases, including the poorly differentiated chordoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27635948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In this study, we considered immunohistochemistry and SMARCB1/INI1 mutational status to examine SMARCB1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27635948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "pathogenic involvement of SMARCB1/INI1 in childhood chordoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27635948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The diagnosis is all the more challenging that other poorly differentiated cancers lose SMARCB1 expression, such as epithelioid sarcomas (ES), renal medullary carcinomas (RMC) or undifferentiated chordomas (UC)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28427232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Loss of SMARCB1/INI1 expression is considered to be a hallmark for childhood chordomas (CCs)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28825187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Poorly differentiated chordoma with loss of SMARCB1/INI1 expression in pediatric patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28812319",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Identification of loss of SMARCB1/INI1 expression in poorly differentiated (PD) chordoma in pediatric patients suggests that PD chordoma is an entity molecularly distinct from conventional chordoma or atypical teratoid/rhabdoid tumor, which is also characterized by loss of SMARCB1/INI1 expression by inactivating mutation of the SMARCB1/INI gene",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28812319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "So far, around 20 cases of pediatric PD chordoma with loss of SMARCB1/INI1 expression have been reported",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28812319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we report two cases of pediatric PD chordoma with loss of SMARCB1/INI1 expression, which is very rare among the pediatric chordoma types",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28812319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on the clival location and histologic findings along with the loss of SMARCB1/INI1 expression and positivity for nuclear brachyury staining, the final pathologic diagnosis for both cases was PD chordoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28812319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Loss of SMARCB1/INI1 expression is considered to be a hallmark for childhood chordomas (CCs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28825187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The diagnosis is all the more challenging that other poorly differentiated cancers lose SMARCB1 expression, such as epithelioid sarcomas (ES), renal medullary carcinomas (RMC) or undifferentiated chordomas (UC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28427232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28825187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "smarcb1 ini1 involvement in pediatric chordoma a mutational and immunohistochemical analysis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27635948",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27635948",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "chordomas, childhood chordomas, infantile chordomas, CCs"
}